Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5‐hydroxytryptamine receptor (type 3) antagonist
- 1 April 1990
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 4 (2) , 139-144
- https://doi.org/10.1111/j.1365-2036.1990.tb00458.x
Abstract
Ondansetron (GR38032F) is a selective antagonist of 5-hydroxytryptamine (5-HT) type 3 receptors. This randomized, doubleblind, cross-over study was undertaken to evaluate and compare the effect of ondansetron with placebo on gastrointestinal transit in 10 healthy male volunteers. There were no significant differences between the effects of placebo and ondansetron on gastric emptying or mouth-to-caecum transit time. However, significant differences in mean whole-gut transit time were observed, that is 54.8 h with ondansetron and 32.1 h with placebo. Therefore, 5-HT3 receptors may be involved in the regulation of colonic transit and ondansetron may prove useful as an anti-diarrhoeal agent.This publication has 9 references indexed in Scilit:
- 5-HT: The Enigma VariationsTrends in Pharmacological Sciences, 1987
- PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONISTThe Lancet, 1987
- Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamineNeuropharmacology, 1986
- THE IRRITABLE BOWEL SYNDROME: A PAROXYSMAL MOTOR DISORDERThe Lancet, 1985
- Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns.Gut, 1983
- The two‐period cross‐over clinical trial.British Journal of Clinical Pharmacology, 1979
- Transit through the gut measured by analysis of a single stool.Gut, 1976
- Simple clinical method of measuring gastric emptying of solid meals.Gut, 1976
- TWO KINDS OF TRYPTAMINE RECEPTORBritish Journal of Pharmacology and Chemotherapy, 1957